Opportunities for gene therapy in preventing vein graft failure after coronary artery bypass surgery

Baker, A., Yim, A. and Wan, S. (2006) Opportunities for gene therapy in preventing vein graft failure after coronary artery bypass surgery. Diabetes, Obesity and Metabolism, 8(2), pp. 119-124. (doi:10.1111/j.1463-1326.2005.00494.x) (PMID:16448515)

Full text not currently available from Enlighten.

Abstract

The poor patency rates for coronary artery bypass grafting (CABG) using autologous saphenous vein necessitate the need for continued research into the potential clinical utility of gene therapy. Bypass grafting is ideally suited for gene therapy, as graft can be genetically modified ex vivo prior to grafting in the coronary vasculature. Research to date has demonstrated effective blockade of late vein graft failure through overexpression of a variety of transgenes that modulate the proliferative, migratory and/or apoptotic indexes of cells in the graft wall. This has resulted in a substantial wealth of preclinical data that support advancement to clinical trials. Future translation into clinical trials will ensure that this exciting and highly relevant area of gene therapy is fully evaluated for potential routine clinical practice to improve patency rates of bypass graft procedures involving saphenous vein.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Baker, Professor Andrew
Authors: Baker, A., Yim, A., and Wan, S.
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Diabetes, Obesity and Metabolism
Publisher:Wiley
ISSN:1462-8902
Published Online:25 April 2005

University Staff: Request a correction | Enlighten Editors: Update this record